Pfizer
This article was originally published in The Tan Sheet
Executive Summary
"Strong" sales growth of Sudafed, Benadryl, Zantac 75 and Lubriderm helped offset "a mild cough/cold season in Europe" in first quarter, firm tells analysts April 18. Warner-Lambert Consumer Group sales fell 2% to $591 mil. in period; excluding effect of currency exchange, segment revenues were flat. Consolidated revenues increased 7% to $7.65 bil., led by human pharmaceuticals sales, which jumped 11% to $6.05 bil. Overall sales growth was reduced by about 3% ($229 mil.) due to foreign exchange and roughly 2% ($103 mil.) as a result of the withdrawal of Rx diabetes drug Rezulin
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning